ECSP10010333A - Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado - Google Patents

Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado

Info

Publication number
ECSP10010333A
ECSP10010333A EC2010010333A ECSP10010333A ECSP10010333A EC SP10010333 A ECSP10010333 A EC SP10010333A EC 2010010333 A EC2010010333 A EC 2010010333A EC SP10010333 A ECSP10010333 A EC SP10010333A EC SP10010333 A ECSP10010333 A EC SP10010333A
Authority
EC
Ecuador
Prior art keywords
amino acid
residue
action profile
delayed time
insulin derivatives
Prior art date
Application number
EC2010010333A
Other languages
English (en)
Inventor
Norbert Tennagels
Guenter Mueller
Paul Habermann
Gerhard Seipke
Roland Kurrle
Mark Sommerfeld
Georg Tschank
Ulrich Werner
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010333(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE200810003568 external-priority patent/DE102008003568A1/de
Priority claimed from DE200810025008 external-priority patent/DE102008025008A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of ECSP10010333A publication Critical patent/ECSP10010333A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a nuevos análogos de insulina con un perfil de tiempo/acción basal que se caracterizan por los rasgos de que a) el extremo de la cadena B consiste en un residuo aminoácido de carácter básico, amidado, tal como lisina o argininamida, b) el residuo de aminoácido N-terminal de la cadena A de la insulina es un residuo lisina o arginina, c) la posición A8 del aminoácido está ocupada por un residuo histidina, d) la posición A21 del aminoácido está ocupada por un residuo glicina, y e) se efectúan una o más sustituciones y/o adiciones de residuos aminoácidos negativamente cargados en las posiciones A5, A15, A18, B-1, B0, B1, B2, B3 y B4.
EC2010010333A 2008-01-09 2010-07-08 Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado ECSP10010333A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE200810003568 DE102008003568A1 (de) 2008-01-09 2008-01-09 Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US4465908P 2008-04-14 2008-04-14
DE200810025008 DE102008025008A1 (de) 2008-05-24 2008-05-24 Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil

Publications (1)

Publication Number Publication Date
ECSP10010333A true ECSP10010333A (es) 2010-08-31

Family

ID=40568276

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010333A ECSP10010333A (es) 2008-01-09 2010-07-08 Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado

Country Status (32)

Country Link
US (1) US9644017B2 (es)
EP (1) EP2229407B1 (es)
JP (1) JP5694779B2 (es)
KR (1) KR20100111682A (es)
CN (1) CN102007143B (es)
AR (1) AR070118A1 (es)
AU (1) AU2009203809B2 (es)
BR (1) BRPI0907371A2 (es)
CA (1) CA2711749A1 (es)
CL (1) CL2009000017A1 (es)
CO (1) CO6311108A2 (es)
DK (1) DK2229407T3 (es)
DO (1) DOP2010000209A (es)
EC (1) ECSP10010333A (es)
ES (1) ES2613152T3 (es)
GT (1) GT201000199A (es)
HK (1) HK1149772A1 (es)
HU (1) HUE030537T2 (es)
IL (1) IL206844A (es)
MA (1) MA31998B1 (es)
MY (1) MY152979A (es)
NI (1) NI201000114A (es)
NZ (1) NZ586590A (es)
PA (1) PA8811601A1 (es)
PE (1) PE20091377A1 (es)
PL (1) PL2229407T3 (es)
RU (1) RU2524423C2 (es)
TN (1) TN2010000298A1 (es)
TW (1) TW200942256A (es)
UY (1) UY31596A1 (es)
WO (1) WO2009087081A2 (es)
ZA (1) ZA201003926B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046113A1 (de) * 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
AU2009203810B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
BRPI0911571A2 (pt) * 2008-04-22 2018-04-03 Univ Case Western Reserve método para tratar um mamífero, análogo de insulina, ácido nucléico e célula hospedeira
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
CA2747112A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
NZ593813A (en) 2008-12-15 2013-02-22 Zealand Pharma As Glucagon analogues
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
ES2439499T3 (es) 2008-12-15 2014-01-23 Zealand Pharma A/S Análogos de glucagón
EP2451472A1 (de) * 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Hitze- und schüttelstabile insulinzubereitungen
NZ597757A (en) * 2009-07-06 2014-06-27 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
TW201113032A (en) * 2009-07-06 2011-04-16 Sanofi Aventis Deutschland Slow-acting insulin preparations
NZ597981A (en) 2009-07-13 2014-02-28 Zealand Pharma As Acylated glucagon analogues
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
RU2537239C2 (ru) * 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
PT2498801T (pt) 2009-11-13 2018-05-02 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendin-4(1-39)-lys6-nh2 e metionina
US9079975B2 (en) 2009-12-11 2015-07-14 Case Western Reserve University Insulin analogues with chlorinated amino acids
CN102985440B (zh) 2010-06-23 2016-10-26 诺沃-诺迪斯克有限公司 包含额外的二硫键的胰岛素衍生物
US8883722B2 (en) 2010-06-23 2014-11-11 Novo Nordisk A/S Human insulin containing additional disulfide bonds
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
NZ604208A (en) 2010-06-24 2014-10-31 Zealand Pharma As Glucagon analogues
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
ES2550357T3 (es) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9006176B2 (en) * 2011-10-18 2015-04-14 AmideBio LLC Chemically and thermodynamically stable insulin analogues and improved methods for their production
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
BR112015001451B1 (pt) 2012-07-23 2022-03-29 Zealand Pharma A/S Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
ES2653765T3 (es) 2012-12-21 2018-02-08 Sanofi Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
US9163073B2 (en) 2013-04-17 2015-10-20 Amidebio, Llc Chemically and thermodynamically stable insulin analogues and improved methods for their production
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MY176022A (en) 2013-10-17 2020-07-21 Boehringer Ingelheim Int Acylated glucagon analogues
EP3065767B1 (en) 2013-11-06 2020-12-30 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CA2932875A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
EP3091964A1 (en) 2014-01-09 2016-11-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
PE20161153A1 (es) 2014-01-20 2016-10-27 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
CN107108716A (zh) 2014-10-06 2017-08-29 卡斯西部储备大学 双相性单链胰岛素类似物
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
HUE062573T2 (hu) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Glargin inzulin/lixiszenatid rögzített arányú készítmény
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CA2980978A1 (en) 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
EP3517544A4 (en) 2016-09-23 2020-06-03 Hanmi Pharm. Co., Ltd. INSULIN ANALOG HAVING REDUCED INSULIN RECEPTOR BINDING FORCE AND USE THEREOF
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984696A (en) 1974-12-11 1976-10-05 Medi-Ray, Inc. Radiation guard for X-ray table
JPS6033474B2 (ja) 1978-05-11 1985-08-02 藤沢薬品工業株式会社 新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
AU612141B2 (en) 1987-02-25 1991-07-04 Novo Nordisk A/S Novel insulin derivatives
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
US4923162A (en) 1988-09-19 1990-05-08 Fleming Matthew C Radiation shield swivel mount
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5225323A (en) * 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
US5006718A (en) 1989-07-21 1991-04-09 Lenhart Mark J X-ray shield for X-ray examination table
GR1005153B (el) 1989-08-29 2006-03-13 The General Hospital Corporation Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
DE4405388A1 (de) 1994-02-19 1995-08-24 Hoechst Ag Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
JPH11292787A (ja) 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19637230A1 (de) 1996-09-13 1998-03-19 Boehringer Mannheim Gmbh Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
CZ297682B6 (cs) 1996-06-20 2007-03-07 Novo Nordisk A/S Vodný inzulinový prípravek a zpusob jeho prípravy
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
BR9813111A (pt) 1997-10-24 2000-08-15 Lilly Co Eli Composições de insulina insolúveis
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US5981964A (en) 1997-12-22 1999-11-09 Bruce J. McAuley Adjustable X-ray shield and on-line dosimetry system using same
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
SK12412000A3 (sk) 1998-02-23 2002-05-09 Neurocrine Biosciences, Inc. Metódy liečenia diabetu použitím peptidových analógov inzulínu
JP2002516880A (ja) 1998-06-05 2002-06-11 テクニオン リサーチ アンド デベロップメント ファウンデーション リミテッド インスリンを補った乳児用調製乳
JP2007204498A (ja) 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
DE19947456A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
AU783306B2 (en) 1999-10-04 2005-10-13 Novartis Vaccines And Diagnostics, Inc. Stabilized liquid polypeptide-containing pharmaceutical compositions
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
DE10108211A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
JP4855640B2 (ja) * 2001-04-02 2012-01-18 ノヴォ ノルディスク アー／エス インシュリン前駆体及びその調製方法
EP1432430A4 (en) 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
IL161848A0 (en) * 2001-12-20 2005-11-20 Lilly Co Eli Insulin moldecule having protracted time action
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DK1525219T3 (da) 2002-07-04 2009-09-07 Zealand Pharma As GLP-1 og fremgangsm der til behandling af diabetes
CA2500295A1 (en) * 2002-10-02 2004-04-29 Zealand Pharma A/S Stabilized exendin-4 compounds
WO2004096854A2 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
DE10325567B4 (de) 2003-06-05 2008-03-13 Mavig Gmbh Strahlenschutzanordnung mit separierbarer Umhüllung
WO2005046716A1 (en) 2003-11-13 2005-05-26 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
MX2007000728A (es) * 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
WO2006029634A2 (en) 2004-09-17 2006-03-23 Novo Nordisk A/S Pharmaceutical compositions containing insulin and insulinotropic peptide
DE102004058306A1 (de) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
US20090142338A1 (en) 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
MX2008003362A (es) 2005-09-14 2008-03-25 Sanofi Aventis Deutschland Escision de precursores de insulinas mediante una variante de tripsina.
KR101105871B1 (ko) 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
US9445113B2 (en) 2006-01-10 2016-09-13 Thomson Licensing Methods and apparatus for parallel implementations of 4:4:4 coding
US20070191271A1 (en) 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
WO2007095288A2 (en) 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
US7763582B2 (en) 2006-02-21 2010-07-27 University Of Medicine And Dentistry Of New Jersey Localized insulin delivery for bone healing
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
KR101729986B1 (ko) 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2008145323A1 (en) 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
DK2173407T3 (da) 2007-07-02 2020-04-27 Hoffmann La Roche Anordning til indgivelse af lægemiddel
UA101484C2 (en) 2007-11-01 2013-04-10 Мерк Сероно С.А. Lh liquid formulations
JP5715418B2 (ja) 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー／エス インスリン誘導体
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
AU2009203810B2 (en) * 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
JP2009091363A (ja) 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
TW201113032A (en) 2009-07-06 2011-04-16 Sanofi Aventis Deutschland Slow-acting insulin preparations
EP2451472A1 (de) 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Hitze- und schüttelstabile insulinzubereitungen
NZ597757A (en) 2009-07-06 2014-06-27 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
PT2498801T (pt) 2009-11-13 2018-05-02 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendin-4(1-39)-lys6-nh2 e metionina
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
TW201605489A (zh) 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物

Also Published As

Publication number Publication date
IL206844A0 (en) 2010-12-30
PA8811601A1 (es) 2009-08-26
GT201000199A (es) 2013-11-18
DOP2010000209A (es) 2010-08-31
ZA201003926B (en) 2011-04-28
UY31596A1 (es) 2009-08-31
JP2011509088A (ja) 2011-03-24
AU2009203809B2 (en) 2013-07-25
CO6311108A2 (es) 2011-08-22
DK2229407T3 (en) 2017-02-27
MY152979A (en) 2014-12-15
NZ586590A (en) 2012-06-29
CL2009000017A1 (es) 2009-10-23
US9644017B2 (en) 2017-05-09
WO2009087081A2 (de) 2009-07-16
PL2229407T3 (pl) 2017-06-30
IL206844A (en) 2016-02-29
RU2010133231A (ru) 2012-02-20
HUE030537T2 (en) 2017-05-29
ES2613152T3 (es) 2017-05-22
HK1149772A1 (zh) 2011-10-14
BRPI0907371A2 (pt) 2015-11-24
MA31998B1 (fr) 2011-01-03
WO2009087081A3 (de) 2009-09-17
CN102007143B (zh) 2015-08-26
TW200942256A (en) 2009-10-16
EP2229407B1 (de) 2016-11-16
AR070118A1 (es) 2010-03-17
NI201000114A (es) 2011-03-15
US20110077197A1 (en) 2011-03-31
JP5694779B2 (ja) 2015-04-01
EP2229407A2 (de) 2010-09-22
PE20091377A1 (es) 2009-09-26
CN102007143A (zh) 2011-04-06
AU2009203809A1 (en) 2009-07-16
CA2711749A1 (en) 2009-07-16
TN2010000298A1 (en) 2011-11-11
RU2524423C2 (ru) 2014-07-27
KR20100111682A (ko) 2010-10-15

Similar Documents

Publication Publication Date Title
ECSP10010333A (es) Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado
CR11511A (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
CO6290770A2 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
PE20150900A1 (es) Derivados de exendida-4 como agonistas duales de glp1/glucagon
PE20140579A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
PA8802301A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonistas del glp-1
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
CL2016000873A1 (es) Analogos de glucagon acilado, una composicion que lo comprende; su uso para la fabricacion de un medicamento util para impedir el aumento de peso; un kit y un procedimiento.
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
PE20140186A1 (es) Analogos de glucagon que presentan actividad de receptor de gip
CO7200249A2 (es) Variantes de oxintomodulina de acción prolongada y métodos de producción de las mismas
AR102712A1 (es) Agonistas parciales del receptor de insulina
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
CO2018002328A2 (es) Formulaciones que comprenden variantes de péptido natriurético de tipo c (cnp)
PE20120914A1 (es) Compuestos glucagon activo de receptor de gip
CO6480917A2 (es) Derivados de suero amiloide p, su preparación y uso.
AR081339A1 (es) Conjugados peptidicos
PE20130338A1 (es) Analogos del glucagon
AR092076A1 (es) Proteinas homodimericas
AR102445A1 (es) COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA
MA46146A1 (fr) Insuline a action prolongée et utilisation associée
UY36870A (es) Análogos de insulina novedosos